| Rebif (human IFN-β-1a) / EMD Serono |
PROOF, NCT00599274: Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis |
|
|
| Completed | N/A | 136 | US, Canada, Europe, RoW | Interferon beta-1a, Avonex, Rebif | Biogen | Multiple Sclerosis | | 05/03 | | |
NCT01142557: An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis |
|
|
| Completed | N/A | 522 | Europe | Interferon beta-1a (Rebif), Rebif | Merck KGaA, Darmstadt, Germany, Gesellschaft für Therapieforschung mbH | Multiple Sclerosis | 11/05 | 11/05 | | |
| Completed | N/A | 36 | US | | EMD Serono, Pfizer | Multiple Sclerosis | 10/07 | 02/08 | | |
NCT00137176: EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis |
|
|
| Completed | N/A | 30 | US | Rebif | University of North Carolina, Chapel Hill | Multiple Sclerosis | 10/07 | 10/08 | | |
NCT01142453: An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients |
|
|
| Completed | N/A | 231 | Europe | Interferon beta 1a, Rebif | Merck KGaA, Darmstadt, Germany, Gesellschaft für Therapieforschung mbH | Relapsing-Remitting Multiple Sclerosis | 06/08 | 06/08 | | |
TOURIMS, NCT01142492: A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®) |
|
|
| Completed | N/A | 403 | Europe | Interferon beta-1a, Rebif | Merck KGaA, Darmstadt, Germany | Relapsing-Remitting Multiple Sclerosis | 07/08 | 07/08 | | |
RETURN, NCT01142518: An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone |
|
|
| Completed | N/A | 86 | Europe | Interferon beta 1a, Rebif® | Merck KGaA, Darmstadt, Germany | Relapsing-Remitting Multiple Sclerosis | 03/09 | 03/09 | | |
| Completed | N/A | 290 | Europe | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis | 11/10 | 01/11 | | |
AIMS, NCT01080573: Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis |
|
|
| Completed | N/A | 1257 | Europe | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis | 04/11 | 04/11 | | |
COMPARE, NCT01141751: An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy |
|
|
| Completed | N/A | 334 | Canada | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-Remitting | 06/11 | 06/11 | | |
|
STAR, NCT01080027: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings |
|
|
| Completed | N/A | 254 | Europe | Rebif® New Formulation, Interferon beta1-A | Merck KGaA, Darmstadt, Germany, Merck A.E., Greece, Merck OY, Finland, Merck B.V., Netherlands, Merck A.B., Sweden, Merck, S.A., Portugal | Multiple Sclerosis, Relapsing Remitting | 06/11 | 06/11 | | |
Leptin, NCT01067573: The Role of Serum Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment |
|
|
| Completed | N/A | 20 | US | | University of South Florida, EMD Serono | Multiple Sclerosis | | 07/11 | | |
REPLAY, NCT01207648: Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects |
|
|
| Completed | N/A | 307 | US, Canada, Europe, RoW | Rebif® | EMD Serono | Multiple Sclerosis | 07/11 | 07/11 | | |
NCT01074346: Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis |
|
|
| Completed | N/A | 60 | RoW | Interferon-β-1a, Rebif® | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis | 11/11 | 11/11 | | |
SCANSMART, NCT01125475: A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects |
|
|
| Completed | N/A | 61 | Europe | RebiSmart | Merck KGaA, Darmstadt, Germany, Merck Serono Norway, Smerud Medical Research International AS | Relapsing Remitting Multiple Sclerosis (RRMS) | 03/12 | | | |
|
NCT00391352: fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls |
|
|
| Completed | N/A | 21 | US | IFN-β-1a (Rebif®) | Waukesha Memorial Hospital, The Cleveland Clinic | Relapsing-Remitting Multiple Sclerosis | 08/12 | 08/12 | | |
NCT01112345: An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters |
|
|
| Completed | N/A | 133 | Europe | | Merck KGaA, Darmstadt, Germany, Merck A.E., Greece | Multiple Sclerosis, Relapsing-Remitting | 09/12 | 09/12 | | |
READER, NCT01601080: An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device |
|
|
| Completed | N/A | 230 | Europe | | Merck KGaA, Darmstadt, Germany, Merck Serono Limited, UK | Relapsing Multiple Sclerosis | 10/12 | | | |
| Completed | N/A | 2878 | US | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b, Copaxone®, Avonex®, Rebif®, Betaseron® | Teva Neuroscience, Inc. | Multiple Sclerosis | 12/12 | 01/13 | | |
|
|
|
|
|
|
|
|
SMART, NCT01108887: An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™. |
|
|
| Completed | N/A | 912 | Europe | | Merck KGaA, Darmstadt, Germany, Merck Serono S.A., Geneva | Multiple Sclerosis, Relapsing-Remitting | 01/13 | 01/13 | | |
|
|
ReNew, NCT01101776: Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. |
|
|
| Completed | N/A | 49 | RoW | Interferon beta-1a (Rebif), Rebif New Formulation | Merck KGaA, Darmstadt, Germany, Merck Serono Australia Pty Ltd | Multiple Sclerosis | 04/13 | 04/13 | | |
SKORE, NCT01075880: Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® |
|
|
| Completed | N/A | 300 | Europe | Rebif (Interferon beta-1a), Rebif | Merck KGaA, Darmstadt, Germany, Merck spol.s.r.o., Czech Republic | Multiple Sclerosis, Relapsing-Remitting | 06/13 | 06/13 | | |
MusiClock, NCT01110993: An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) |
|
|
| Completed | N/A | 65 | Europe | | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-Remitting | 09/13 | 09/13 | | |
| Completed | N/A | 198 | Canada | RebiSmart™, Rebif | Merck KGaA, Darmstadt, Germany, EMD Inc., Canada | Multiple Sclerosis, MS | 04/14 | 04/14 | | |
|
|
EMR200136_550, NCT01601119: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients |
|
|
| Completed | N/A | 545 | Europe | Rebif, Other: Disease modifying therapies (DMT) | Merck KGaA, Darmstadt, Germany, Merck Serono Limited, UK | Relapsing Multiple Sclerosis | 07/14 | 07/14 | | |
| Terminated | N/A | 306 | US | Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B | EMD Serono | Multiple Sclerosis, Relapsing-Remitting | 01/15 | 01/15 | | |
| Completed | N/A | 296 | Canada | MACFIMS, MSQoL-54 | Centre hospitalier de l'Université de Montréal (CHUM), EMD Serono Canada Inc. | Multiple Sclerosis | 05/15 | 12/16 | | |
ADHERQOL, NCT02394782: Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis |
|
|
| Terminated | N/A | 8 | Europe | RebiSmart®2.0, MSdialog™ | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-remitting | 11/15 | 03/16 | | |
NCT02419638: Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS |
|
|
| Withdrawn | N/A | 0 | US | Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate) | Brigham and Women's Hospital, EMD Serono | Multiple Sclerosis | 12/15 | 02/16 | | |
PROTRACT, NCT02823951: Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® |
|
|
| Completed | N/A | 479 | US, Canada | Rebif, Tecfidera | IMS HEALTH GmbH & Co. OHG, EMD Serono | Relapsing-remitting Multiple Sclerosis | 04/17 | 02/18 | | |
MESTRE-MS, NCT02949908: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS) |
|
|
| Terminated | N/A | 2 | Europe | Rebif, IFNβ-1b | Merck KGaA, Darmstadt, Germany, Merck B.V., Netherlands | Multiple Sclerosis | 08/17 | 08/17 | | |
